Long-term use of mepolizumab in a case of chronic eosinophilic pneumonia: extending interval dosing.

Abstract

INTRODUCTION:

Mepolizumab, a humanized anti IL-5 monoclonal antibody, has been used off-label for chronic eosinophilic pneumonia (CEP), inducing disease remission and saving systemic corticosteroids.

CASE STUDY:

We present a case of CEP, requiring long-term corticosteroids therapy due to relapse upon withdrawal. Mepolizumab was started and maintained for 2 years and 6 months.

RESULTS:

Corticosteroids could be withdrawn and mepolizumab dose interval was spared up to 10 wk with no disease relapse.

CONCLUSION:

Mepolizumab is shown to be useful for chronic eosinophilic pneumonia, allowing corticosteroid withdrawal. Dose interval may be individualized under close monitoring, for a more efficient treatment, reducing medical costs while improving patients' quality of life.

• Authors: Alicia Prieto-García, María Isabel Peligros, Isabel Pérez Tamayo, José Manuel Zubeldia, Luis Álvarez-Sala, Cristina Lavilla
• Journal: The Journal of asthma : official journal of the Association for the Care of Asthma (J Asthma) Pg. 1-3 (Jul 23 2023) ISSN: 1532-4303 [Electronic] England
• PMID: 37467753 (Publication Type: Journal Article)